Genomic Valley Biotech Ltd (GVBL)

Loading page…

Genomic Valley Biotech Ltd (GVBL) · mywealthgrid

About

Genomic Valley Biotech Ltd operates in Biotechnology within the Healthcare sector.

Face value: ₹10

Market cap

₹9 Cr

P/E

—

P/B

2.2×

Dividend yield

ROE

0.8%

ROCE

Debt / equity

OPM

14.8%

EPS (TTM)

₹-1.8

Book value

₹12.9

52-week high

—

52-week low

—

802 historical price candles were omitted because the exchange source has not been verified.

₹28.9-5%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of 3.7% (3-yr avg)
−Profit declined 64.1% a year over the last 3 years
−Modest revenue growth of 5.2% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

43/100

Business quality: 33
Growth: 0
Valuation: 94

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Anthem Biosciences LimitedANTHEMANTHEM	₹48,213 Cr	₹48,264 Cr	₹2,002 Cr	₹793 Cr	39.3%	₹576 Cr	27.9%	27.6%	19.5%	124
Advanced Enzyme Technologies LimitedADVENZYMESADVENZYMES	₹3,072 Cr	₹3,092 Cr	₹750 Cr	₹224 Cr	30.7%	₹166 Cr	23.3%	13.7%	11.1%	331
CCME Global LtdCCMECCME	₹54 Cr	₹54 Cr	₹0 Cr	₹0 Cr	—	₹4 Cr	—	-2.9%	-2.9%	—
Vivo Bio Tech LtdVIVOBIOTVIVOBIOT	₹38 Cr	₹92 Cr	₹47 Cr	₹21 Cr	44%	₹7 Cr	15.6%	15.2%	11%	517
Shree Ganesh Biotech (India) LtdSHREEGANESSHREEGANES	₹19 Cr	₹19 Cr	₹23 Cr	₹-1 Cr	-19.3%	₹0 Cr	7.7%	0.8%	0.6%	846
Genomic Valley Biotech LtdGVBLGVBL	₹9 Cr	₹9 Cr	₹0 Cr	₹-0 Cr	14.8%	₹-1 Cr	11.1%	1%	0.8%	3,565

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	0	1	1	1	0	0	3	0	1	0
COGS	-0	-0	-0	-0	—	0	0	2	0	0	0
Gross profit	—	—	—	—	—	0	—	1	—	1	—
	1	1	1	1	0	0	0	0	0	0	0
	-0	-0	0	0	1	-0	-0	1	0	0	0
OPM %	-390.9%	-9.1%	17%	42.4%	63.5%	-61.9%	-557.1%	32.4%	11.8%	51.2%	14.8%
Depreciation	0	0	0	0	0	0	0	0	0	0	0
Interest	—	—	—	—	—	0	0	0	0	0	0
	0	0	—	—	—	0	1	-0	0	0	0
Profit before tax	-0	-0	0	0	0	-1	0	1	0	0	0
Tax	—	—	—	—	—	0	0	0	0	0	0
Tax %	—	—	—	—	—	12%	—	0%	0%	20.5%	25%
	-0	-0	0	0	0	-1	-0	1	0	0	0
PAT margin %	-300%	-15.9%	5.1%	23.2%	34.1%	-266.7%	-14.3%	23.9%	11.8%	42.9%	11.1%
EPS (₹)	-1.1	—	0.1	0.8	0.9	-1.8	-0	2.1	0.1	1.2	0.1
EPS adjusted (₹)	—	—	—	—	1	-1.8	-0	2.1	0.1	1.2	0.1
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	3	3	3	3	3	3	3
Reserves	—	1	-0	0	0	1	1
Minority interest	—	0	0	0	—	0	0
	—	2	0	0	0	0	0
	—	2	1	1	1	0	0
Total equity & liabilities	—	8	4	4	4	4	4
	4	6	2	0	0	0	0
CWIP	—	0	0	0	0	0	0
Investments	—	0	0	0	0	0	0
	—	1	2	4	4	4	4
Total assets	—	8	4	4	4	4	4

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1	-2	-1	-0	0	-0
	-2	4	2	-0	0	0
	0	-2	-1	0	0	0
Net cash flow	-0	-0	0	-0	0	-0
Free cash flow	—	—	-1	-0	0	-0
CFO / Operating profit %	—	—	-118.2%	-100%	7%	-50%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	57.1%	—	41.9%	—	75%	—
EBITDA margin %	42.4%	63.5%	-61.9%	-557.1%	32.4%	11.8%	51.2%	14.8%
EBIT margin %	23.2%	42.4%	-152.4%	-671.4%	32%	11.8%	51.2%	14.8%
PAT margin %	23.2%	34.1%	-266.7%	-14.3%	23.9%	11.8%	42.9%	11.1%
Working capital
Receivable days	—	—	104	0	298	5,432	960	3,136
Inventory days	—	—	0	0	0	0	487	444
Payable days	—	—	162	0	141	1,460	17	16
NWC days	—	—	-58	0	157	3,972	1,430	3,565
Leverage
Current ratio	—	—	0.18	5.43	2.9	3.68	5.7	8.44
Debt to EBITDA	—	—	—	—	0	0	0	0
Debt to equity	—	—	0.35	0	0	0	0	0
Interest coverage	—	—	-1.8	-9.8	—	—	—	—
Asset turnover	—	—	0.03	0.02	0.62	0.04	0.19	0.06
Return ratios
Return on assets %	—	—	-7.3%	-0.3%	14.7%	0.5%	8.3%	0.7%
Return on capital employed %	—	—	-4.7%	-7.5%	25.6%	0.6%	11.6%	1%
Return on equity %	—	—	-12.5%	-0.3%	18.5%	0.6%	9.3%	0.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	66.32%	65.04%	64.2%	64.14%	54.67%	46.83%	46.78%	46.72%	46.72%	46.06%	46.06%	46.06%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	33.68%	34.96%	35.8%	35.86%	45.33%	53.17%	53.22%	53.28%	53.28%	53.94%	53.94%	53.94%
No. of shareholders	—	—	—	—	—	—	—	—	2,459	2,522	2,481	2,448

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Genomic Valley Biotech Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

6 announcementsExport CSV

28 Sept 2026, 8:40 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

31 Aug 2026, 3:33 pmOthers

Intimation Of Approval Of Extension Of Time For Holding Annual General Meeting (AGM) Of The Company For The Financial Year Ended On 31St March 2026, Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Exchange filing PDF

17 Aug 2026, 9:21 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

14 Aug 2026, 4:35 pmResult

Results-Financial Results For Quarter Ended On 30 June 2026.

Financial Results PDF

14 Aug 2026, 3:59 pmBoard Meeting

Board Meeting Outcome for Outcome Of The Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Held On Today I.E. 14Th August 2026

Outcome of Board Meeting PDF

6 Jul 2026, 3:17 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

Date	Category	Subject	Filing
28 Sept 2026, 8:40 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
31 Aug 2026, 3:33 pm	Others	Intimation Of Approval Of Extension Of Time For Holding Annual General Meeting (AGM) Of The Company For The Financial Year Ended On 31St March 2026, Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	57.1%	—	41.9%	—	75%	—
EBITDA margin %	42.4%	63.5%	-61.9%	-557.1%	32.4%	11.8%	51.2%	14.8%
EBIT margin %	23.2%	42.4%	-152.4%	-671.4%	32%	11.8%	51.2%	14.8%
PAT margin %	23.2%	34.1%	-266.7%	-14.3%	23.9%	11.8%	42.9%	11.1%
Working capital
Receivable days	—	—	104	0	298	5,432	960	3,136
Inventory days	—	—	0	0	0	0	487	444
Payable days	—	—	162	0	141	1,460	17	16
NWC days	—	—	-58	0	157	3,972	1,430	3,565
Leverage
Current ratio	—	—	0.18	5.43	2.9	3.68	5.7	8.44
Debt to EBITDA	—	—	—	—	0	0	0	0
Debt to equity	—	—	0.35	0	0	0	0	0
Interest coverage	—	—	-1.8	-9.8	—	—	—	—
Asset turnover	—	—	0.03	0.02	0.62	0.04	0.19	0.06
Return ratios
Return on assets %	—	—	-7.3%	-0.3%	14.7%	0.5%	8.3%	0.7%
Return on capital employed %	—	—	-4.7%	-7.5%	25.6%	0.6%	11.6%	1%
Return on equity %	—	—	-12.5%	-0.3%	18.5%	0.6%	9.3%	0.8%

22 deals · 13 Feb 2023 – 22 Jan 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
22 Jan 2026	KIRORI MAL SANGHI	Bulk	BSE	Buy	19,933	₹24.99	₹0.05 Cr
25 Oct 2024	YOGESH AGRAWAL	Bulk	BSE	Sell	48,032	₹98.46	₹0.47 Cr
23 Oct 2024	SATISH KUMAR SHARMA	Bulk	BSE	Sell	21,978	₹96.86	₹0.21 Cr
22 Oct 2024	YOGESH AGRAWAL	Bulk	BSE	Sell	20,000	₹99.10	₹0.20 Cr
22 Oct 2024	PURUSHOTHAMAN SHAJI	Bulk	BSE	Buy	18,580	₹98.45	₹0.18 Cr
21 Oct 2024	SATISH KUMAR SHARMA	Bulk	BSE	Sell	22,322	₹99.41	₹0.22 Cr
18 Oct 2024	VIKRAMASHOKKUMARJAIN	Bulk	BSE	Buy	79,000	₹94.25	₹0.74 Cr
18 Oct 2024	SATISH KUMAR SHARMA	Bulk	BSE	Sell	25,400	₹94.25	₹0.24 Cr
18 Oct 2024	PARUL AGRAWAL	Bulk	BSE	Sell	19,756	₹94.25	₹0.19 Cr
16 Oct 2024	VIKRAMASHOKKUMARJAIN	Bulk	BSE	Buy	81,000	₹92.43	₹0.75 Cr

1–10 of 22

1 / 3

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Genomic Valley Biotech Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

Announcements

Not in the F&O segment

No fund holdings on record

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Genomic Valley Biotech Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Board meetings1

Announcements

Quarterly record

Annual reports

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1